Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Siterone TM

Active ingredients: cyproterone

What it is used for

Women: Moderately severe to severe signs of androgenisation. Moderately severe/severe forms of hirsutism. Moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe andogenetic alopecia). Moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. Cyproterone acetate inhibits the influence of male sex hormones, which are also produced by the female. It is thus possible to treat diseases in women caused either by increases production of androgens or a particular sensitivity to these hormones. Hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. If Meditab Cyproterone is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. Therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyl oestradiol taken as well to ensure contraception. This also promotes regular menstruation. . Men: Reduction of drive in sexual deviations. Meditab Cyproterone reduces the force of the sexual urge in men with sexual deviations. Whilst under treatment, the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. Abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. A prerequisite for therapy is the desire by the patient for treatment. Meditab Cyproterone therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation. Inoperable prostatic carcinoma. To suppress "Flare" with initial LHRH analogue therapy. In long term palliative treatment where LHRH analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. In the treatment of hot flushes in patients treated with LHRH analogues or who have had orchidectomy..

How to take it

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

  • The way to take this medicine: Oral
  • Store below 25 degrees Celsius
  • Shelf lifetime is 3 Years.

Always read the label. If symptoms persist see your healthcare professional.

Visual appearance

WHITE, CIRCULAR, FLAT-BEVELED WITH BREAKLINE ON ONE SIDE, PLAIN ON THE OTHER DIAMETER: 8.5MM. THICKNESS: 2.7MM.

Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.

Pregnant or planning a pregnancy?

For the active ingredient cyproterone

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Back to top back to top

Healthdirect 24hr 7 days a week hotline

24 hour health advice you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information and advice

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo